Host: Barnett Mennen, MD

Guest: Michael Postow, MD

Immunotherapy, notably overcoming checkpoint inhibition, has become an integral part of treatment for melanoma, if not a growing list of other cancers. In this activity, Dr. Michael Postow discusses major updates on the use of immunotherapy in melanoma as presented at the 13th International Congress of the Society for Melanoma Research that took place recently in Boston, Massachusetts. Topics include the general mechanistic principles behind immune checkpoint blockade in the treatment of metastatic melanoma; the current landscape of immune checkpoint inhibitors; and considerations for single agent vs. combination immunotherapy. Additionally, Dr. Postow will address the current value of immunotherapy biomarkers in patient selection and the independent and/or combined roles of immunotherapy and targeted therapy in the treatment of melanoma.